Chemistry trick renews hope against killer diseases

Dec 28, 2011
As infections such as tuberculosis have become immune to an ever widening range of antibiotics, doctors have looked on helplessly. Now a chemist at the University of Copenhagen has pioneered a novel way to battle multidrug resistant bacteria. By tweaking a well known psychoactive drug he revitalizes worn-out drugs like sulpha and penicillin. Credit: Photo: Jes Andersen/University of Copenhagen

As infections such as tuberculosis have become immune to an ever widening range of antibiotics doctors have looked on helplessly.

Now a Danish chemist has pioneered a novel way to battle multidrug . By tweaking a well known psychoactive drug he revitalizes worn-out drugs like sulpha and penicillin.

Chemist Jorn Bolstad Christensen of the University of Copenhagen has just patented the use of medication Thioridazin in boosting the effect of antibiotics. Christensen is an associate professor at the Department of Chemistry, University of Copenhagen, and in the lab he started investigating how the schizophrenia drug might bother but not humans.

"Thioridazin blocks the capacity of bacteria to cleanse themselves of antibiotics. We knew that before starting. But I wanted to remove the action of the drug in the brain so that mortally ill patients wouldn't have to contend with psychoactive effects as a part of their cure," explains Christensen, who none the less had to come to terms with a much bigger threat as well.

Bacteria such as those responsible for tuberculosis, and enterococcus get rid of using their so called efflux-pump. A mechanism which simply pumps the active substance out of the cell before it has an opportunity to do harm. A substance which blocks the pump should ensure that any antibiotic stays inside the bacteria long enough to kill it. There's just one tiny problem. have efflux pumps as well. And we wouldn't want these blocked.

"The task was to find a substance that will kill bacteria, but not the patients taking the cure. Thioridazin was a good candidate because it's been in use for decades. We could be pretty certain that it wouldn't have any serious side effects," says professor Christensen, who predicts testing the new drug in humans within just a year, as it's already been approved for other medical uses.

Though the risk of blocking the efflux pump of human cells appeared minimal Professor Christensen still needed to minimize the psychoactive effects of the . This was where his chemical expertise became indispensable. Chemically Thioridazin consists of two half molecules which are perfect mirror images. One of these mirror- or isomeric forms affects the brain less than the other, so the question was whether bacteria would know the difference.

Doctors and researchers Jette Kristiansen and Oliver Hendricks of Southern University Denmark who are co-holders of the patent have conducted microbiological trials proving that the efflux pump of bacteria stayed blocked regardless of which isomer was used. These results open up a brand new method for combating problems of multidrug resistance.

Explore further: Metabolism may have started in our early oceans before the origin of life

Provided by University of Copenhagen

5 /5 (6 votes)
add to favorites email to friend print save as pdf

Related Stories

New compound defeats drug-resistant bacteria

Nov 28, 2011

It's no wonder that medicine's effort to combat bacterial infections is often described as an arms race. When new drugs are developed to combat infections, the bacterial target invariably comes up with a deterrent.

Recommended for you

New method to analyse how cancer cells die

21 hours ago

(Phys.org) —A team from The University of Manchester – part of the Manchester Cancer Research Centre - have found a new method to more efficiently manufacture a chemical used to monitor cancer cells.

The anti-inflammatory factory

Apr 22, 2014

Russian scientists, in collaboration with their colleagues from Pittsburgh University, have discovered how lipid mediators are produced. The relevant paper was published in Nature Chemistry. Lipid mediators are molecules that p ...

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

Osiris1
1 / 5 (1) Dec 29, 2011
Maybe also why 'mental cases' did not seem to get sick or stay sick often.

More news stories

Computer program could help solve arson cases

Sifting through the chemical clues left behind by arson is delicate, time-consuming work, but University of Alberta researchers teaming with RCMP scientists in Canada, have found a way to speed the process.

Google+ boss leaving the company

The executive credited with bringing the Google+ social network to life is leaving the Internet colossus after playing a key role there for nearly eight years.

Facebook woos journalists with 'FB Newswire'

Facebook launched Thursday FB Newswire, billed as an online trove of real-time information for journalists and newsrooms to mine while reporting on events or crafting stories.